NASDAQ:APLS

Apellis Pharmaceuticals - APLS Price Target & Analyst Ratings

$63.05

+0.03 (+0.05%)

(As of 03/20/2023 12:00 AM ET)

Add

Compare

Today's Range: $60.88
▼
$63.44
50-Day Range: $49.02
▼
$66.96
52-Week Range: $33.32
▼
$70.75

Volume: 1.34 million shs
Average Volume: 1.72 million shs
Market Capitalization: $7.02 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $78.40

Institutional Ownership

Apellis Pharmaceuticals Consensus Rating and Price Target (2023)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

Moderate Buy
Based on 14 Analyst Ratings

Consensus Analyst Price Target

$78.40
24.35% Upside

High Prediction	$139.00
Average Prediction	$78.40
Low Prediction	$40.00

Type	Current 3/20/22 to 3/20/23	1 Month Ago 2/18/22 to 2/18/23	3 Months Ago 12/20/21 to 12/20/22	1 Year Ago 3/20/21 to 3/20/22
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy
Strong Buy	1 Strong Buy rating(s)	1 Strong Buy rating(s)	1 Strong Buy rating(s)	2 Strong Buy rating(s)
Buy	8 Buy rating(s)	7 Buy rating(s)	8 Buy rating(s)	10 Buy rating(s)
Hold	4 Hold rating(s)	4 Hold rating(s)	3 Hold rating(s)	3 Hold rating(s)
Sell	1 Sell rating(s)	1 Sell rating(s)	1 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$78.40	$71.23	$72.15	$72.80
Predicted Upside	24.35% Upside	33.21% Upside	35.66% Upside	49.30% Upside

Get Apellis Pharmaceuticals Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for APLS and its competitors with MarketBeat's FREE daily newsletter.

APLS Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

APLS Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Apellis Pharmaceuticals Stock vs. The Competition

Type	Apellis Pharmaceuticals	Medical Companies	S&P 500
Consensus Rating Score	2.64	2.64	2.47
Consensus Rating	Moderate Buy	Buy	Hold
Predicted Upside	24.52% Upside	1,930.62% Upside	22.67% Upside
News Sentiment Rating	Positive News	Neutral News	Neutral News

Historical Target Prices and Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
3/9/2023	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$91.00 ➝ $88.00	+35.87%
2/22/2023	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Strong-Buy	$123.00 ➝ $139.00	+137.61%
2/21/2023	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target		$79.00 ➝ $115.00	+107.24%
2/21/2023	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy	$65.00 ➝ $75.00	+35.16%
2/21/2023	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform	$90.00 ➝ $105.00	+89.22%
2/21/2023	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy	$75.00 ➝ $87.00	+56.78%

2/21/2023	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy	$70.00 ➝ $80.00	+44.17%
1/2/2023	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Overweight ➝ Equal Weight	$83.00 ➝ $58.00	+12.16%
11/15/2022	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight	$81.00 ➝ $79.00	+70.92%
11/10/2022	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Hold	$70.00 ➝ $40.00	-9.07%
11/8/2022	Credit Suisse Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Neutral	$45.00 ➝ $43.00	-9.70%
11/8/2022	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$59.00 ➝ $47.00	-1.30%
8/18/2022	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform	$68.00 ➝ $78.00	+13.59%
8/9/2022	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy	$91.00 ➝ $102.00	+63.65%
4/13/2022	Roth Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	E. Piros Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Neutral ➝ Sell	$40.00	-25.39%
9/10/2021	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform	$89.00 ➝ $69.00	+98.28%
7/1/2021	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform	$60.00 ➝ $70.00	+10.10%
5/20/2021	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$82.00	+67.42%
11/23/2020	Smith Barney Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target		$53.00 ➝ $67.00	+39.55%
10/9/2020	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	A. Young Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight
6/16/2020	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Neutral

(Data available from 3/20/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)

APLS Price Target - Frequently Asked Questions

What is Apellis Pharmaceuticals's consensus rating and price target?: According to the issued ratings of 14 analysts in the last year, the consensus rating for Apellis Pharmaceuticals stock is Moderate Buy based on the current 1 sell rating, 4 hold ratings, 8 buy ratings and 1 strong buy rating for APLS. The average twelve-month price prediction for Apellis Pharmaceuticals is $78.40 with a high price target of $139.00 and a low price target of $40.00. Learn more on APLS's analyst rating history.
Do Wall Street analysts like Apellis Pharmaceuticals more than its competitors?: Analysts like Apellis Pharmaceuticals more than other Medical companies. The consensus rating for Apellis Pharmaceuticals is Moderate Buy while the average consensus rating for medical companies is Buy. Learn more on how APLS compares to other companies.
Is Apellis Pharmaceuticals being downgraded by Wall Street analysts?: Over the previous 90 days, Apellis Pharmaceuticals's stock had 1 downgrade by analysts.

Does Apellis Pharmaceuticals's stock price have much upside?: According to analysts, Apellis Pharmaceuticals's stock has a predicted upside of 42.09% based on their 12-month price targets.
What analysts cover Apellis Pharmaceuticals?: Apellis Pharmaceuticals has been rated by Bank of America, Citigroup, HC Wainwright, Needham & Company LLC, Raymond James, Robert W. Baird, Stifel Nicolaus, and Wells Fargo & Company in the past 90 days.

Stock Ratings Reports and Tools

Today's Ratings:

Top Rated Stocks:

More Ratings Tools:

Ratings for Popular Stocks:

This page (NASDAQ:APLS) was last updated on 3/20/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial